



Brussels, 31.5.2017
C(2017) 3892 final

COMMISSION IMPLEMENTING DECISION

of 31.5.2017

**transferring and amending the marketing authorisation granted by Decision C(2000)576
for "Azopt - Brinzolamide", a medicinal product for human use**

(Text with EEA relevance)

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

COMMISSION IMPLEMENTING DECISION

of 31.5.2017

transferring and amending the marketing authorisation granted by Decision C(2000)576 for "Azopt - Brinzolamide", a medicinal product for human use

(Text with EEA relevance)

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency¹,

Having regard to Commission Regulation (EC) No 2141/96 of 7 November 1996 concerning the examination of an application for the transfer of a marketing authorisation for a medicinal product falling within the scope of Council Regulation (EEC) No 2309/93², and in particular Article 6 thereof,

Having regard to the application submitted by Alcon Laboratories (UK) Ltd on 1 April 2017 under Article 3 of Regulation (EC) No 2141/96,

Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use³, and in particular Article 61(3) thereof,

Having regard to the changes to the terms of the decision granting the marketing authorisation requested by Alcon Laboratories (UK) Ltd in accordance with Article 61(3) of Directive 2001/83/EC,

Having regard to the opinion of the European Medicines Agency, formulated on 6 April 2017 on the transfer of a marketing authorisation,

Whereas:

- (1) The medicinal product "Azopt - Brinzolamide", entered in the Community register of medicinal products under the number EU/1/00/129 and authorised by Commission Decision C(2000)576 of 9 March 2000, remains in compliance with the requirements set out in Directive 2001/83/EC of the European Parliament and of the Council of 6

¹ OJ L 136, 30.4.2004, p. 1.

² OJ L 286, 8.11.1996, p. 6.

³ OJ L 311, 28.11.2001, p. 67.

November 2001 on the Community code relating to medicinal products for human use⁴.

- (2) A change of holder of the marketing authorisation for which the transfer application is made is a change of an administrative nature, which does not affect the scientific characteristics of the medicinal product already authorised.
- (3) It is appropriate to set the date by which all the operations resulting from the transfer of the marketing authorisation must be completed.
- (4) The European Medicines Agency has given a favourable opinion.
- (5) Decision C(2000)576 should therefore be amended accordingly. The Community Register of Medicinal Products should also be updated.
- (6) For the sake of clarity and transparency, it is appropriate, following the amendment of part or parts of the Annexes, to provide for a consolidated version thereof. The Annexes to Decision C(2000)576 should therefore be replaced.

HAS ADOPTED THIS DECISION:

Article 1

The marketing authorisation granted by Decision C(2000)576 of 9 March 2000 to Alcon Laboratories (UK) Ltd for the medicinal product "Azopt - Brinzolamide", entered in the Community register of medicinal products under No EU/1/00/129, is transferred to Novartis Europharm Limited.

Article 2

Decision C(2000)576 is amended as follows:

- 1) Annex I is replaced by the text set out in Annex I to this Decision;
- 2) Annex II is replaced by the text set out in Annex II to this Decision;
- 3) Annex III is replaced by the text set out in Annex III to this Decision.

Article 3

- 1) The transfer referred to in Article 1 shall be authorised from the date of notification of this Decision.
- 2) All the operations resulting from this transfer must be completed by 1 June 2018 at the latest.

⁴ OJ L 311, 28.11.2001, p. 67.

Article 4

This Decision is addressed to:

1. Novartis Europharm Limited, Frimley Business Park, Camberley GU16 7SR, United Kingdom

and

2. Alcon Laboratories (UK) Ltd, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom.

Done at Brussels, 31.5.2017

For the Commission

Xavier PRATS MONNÉ

Director-General

